Annual report to shareholders
Open the filing on sec.gov
Celularity Inc. (CELU)
Nasdaq: CELU · Pharmaceutical Preparations · Florham Park, NJ · filing with the SEC since 2018
The companyfiscal 2025, as filed
Revenue$26.6M-51.0%
Net income-$91.7M-58.4%
Earnings per share$-3.59-36.0%
Operating cash flow-$13.3M-107.1%
Cash$6.2M+736.7%
Debt$33.8M
Shareholders’ equity-$38.1M-530.7%
Shares, diluted25.6M+16.9%
Return on equityn/a
The recordfrom its filings
Filings in 202656
Newest filingNov 10 · ARS
Annual reportApr 30, 2026
Quarterly reportOct 20, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted19
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Revenue $18.7MNet income -$45.9MCash from operations -$8.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Annual report, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.